There is now accumulating evidence, showing that a sodium-glucose cotransporter-2 inhibitor (SGLT2i) has distinct beneficial effects on renal and cardiovascular outcomes of patients with type 2 diabetes mellitus (DM) [6, 7]. The gene discussed is SLC5A2; the disease is diabetes mellitus.